Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neuronetics, Inc. (NASDAQ: STIM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Neuronetics is a commercial stage medical technology and healthcare company focused on NeuroStar Advanced Therapy, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment, and on operating Greenbrook TMS treatment centers across the United States. Its filings offer detailed insight into how this device-and-clinic model is reflected in reported revenues, capital structure, and risk disclosures.
Among the most relevant documents for STIM are current reports on Form 8-K, which Neuronetics uses to announce quarterly financial and operating results, amendments to its credit agreement with Perceptive Credit Holdings IV, LP, and other material events. These filings confirm that the company’s common stock is listed on The Nasdaq Global Market and provide information on revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue from Greenbrook centers. Form 8-Ks also describe leadership changes, such as the appointment of a new Chief Financial Officer and a planned CEO retirement, and summarize key terms of executive employment and compensation arrangements.
Investors reviewing Neuronetics’ filings can also examine disclosures about its credit facility, including additional borrowing tranches, minimum liquidity requirements, and associated warrant issuances. Safe harbor statements in these reports outline forward-looking risks related to reliance on NeuroStar Advanced Therapy System sales and usage, payer coverage and reimbursement for TMS treatments, competition from other technologies, and the integration of Greenbrook’s clinic business.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly see how Neuronetics presents its business model, revenue drivers, and risk factors, and can also track insider and equity-related activity through filings that describe inducement equity awards and warrant issuances. Real-time updates from EDGAR ensure that new Neuronetics filings, including financial results and material agreements, are available promptly with simplified explanations for faster analysis.
Neuronetics, Inc. executive William Andrew Macan, EVP, CLO and CS, reported selling 3,485 shares of common stock on February 10, 2026. The Form 4 notes these were non-discretionary sales made solely to satisfy tax withholding on the vesting of a restricted stock unit award, at a weighted average price of $1.55 per share. After this transaction, Macan directly beneficially owned 687,681 shares of Neuronetics common stock.
Neuronetics, Inc. President and CEO Keith J. Sullivan reported an open-market sale of 40,976 shares of common stock on February 10, 2026 at a weighted average price of $1.55 per share. According to the disclosure, these were non-discretionary sales made solely to satisfy his tax withholding obligation upon the vesting of a portion of a restricted stock unit award.
After this transaction, Sullivan directly beneficially owned 1,567,012 shares of Neuronetics common stock.
STIM shareholder Keith Sullivan filed a notice of proposed sale of 33,847 shares of common stock. The shares are expected to be sold through Fidelity Brokerage Services on NASDAQ around 02/12/2026, with an indicated aggregate market value of $55,712.16.
The 33,847 shares came from restricted stock that vested on 02/09/2026 as compensation from the issuer. The filing notes 68,485,922 common shares outstanding. Over the prior three months, Sullivan also sold 40,976 common shares for gross proceeds of $63,398.07.
STIM shareholder William A. Macan has filed a Form 144 notice to sell up to 14,120 shares of common stock. The proposed sale, with an aggregate market value of $23,241.52, is planned through Fidelity Brokerage Services LLC on the NASDAQ, with an approximate sale date of 02/12/2026.
The shares were acquired on 02/06/2026 through restricted stock vesting from the issuer as compensation. Over the prior three months, Macan sold 3,485 common shares for gross proceeds of $5,391.99. The filing also states that the seller represents having no undisclosed material adverse information about STIM.
Neuronetics, Inc. reported selected preliminary, unaudited results showing strong growth for the fourth quarter and full year 2025. Fourth quarter 2025 revenue was $41.8 million, up 23% on an adjusted pro‑forma basis and 86% versus reported fourth quarter 2024. NeuroStar revenue was $18.3 million, with 49 NeuroStar Advanced Therapy systems shipped, while clinic revenue reached $23.5 million, up 37% on an adjusted pro‑forma basis.
For full year 2025, revenue was $149.2 million, a 15% increase on an adjusted pro‑forma basis and 99% higher than reported 2024. Full year NeuroStar revenue was $62.2 million, and clinic revenue was $87.0 million, up 28% on an adjusted pro‑forma basis. The company generated positive operating cash flow of $0.9 million in the quarter and ended 2025 with $34.1 million in total cash.
A holder of STIM common stock filed a notice of proposed sale under Rule 144 covering 3,485 shares, with an aggregate market value of $5,391.99, to be sold through Fidelity Brokerage Services LLC on or about 02/10/2026 on the NASDAQ.
The securities were acquired as restricted stock vesting from the issuer on 02/05/2026 as compensation. Shares of the issuer outstanding were 68,485,922 at the time referenced, providing context for the planned sale size.
STIM filed a notice of proposed sale of restricted securities under Rule 144. The filing covers the planned sale of 40,976 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ around February 10, 2026, with an aggregate market value of $63,398.07.
These shares were acquired on February 5, 2026 through restricted stock vesting from the issuer as compensation. Shares outstanding were 68,485,922. The seller represents that they do not know of any undisclosed material adverse information about the issuer’s current or prospective operations.
Investor Jorey Chernett filed an amended Schedule 13G reporting his beneficial ownership in Neuronetics, Inc. common stock. He reports holding 6,827,031 shares, with sole power to vote and dispose of all of these shares and no shared voting or dispositive power.
This stake exceeds the 5% threshold that requires public disclosure but is certified as not intended to change or influence control of Neuronetics. The filing lists Chernett as a U.S. individual investor and indicates no group, subsidiaries, or other persons on whose behalf the shares are held.
Neuronetics, Inc. entered into Amendment No. 4 to its existing Credit Agreement and Guaranty with Perceptive Credit Holdings IV, LP and other lenders. This amendment changes how the company’s subsidiaries are required to join the credit facility as an “Obligor” and “Subsidiary Guarantor”, affecting which subsidiaries must guarantee the company’s debt under this agreement.
The amendment is part of the company’s ongoing relationship with Perceptive and adjusts the guarantee structure rather than creating a new financing arrangement. The full legal terms are contained in the amendment, which is filed as an exhibit to this report.
Neuronetics, Inc. reported that its Compensation Committee approved new cash and restricted stock unit awards for two senior executives. Steven E. Pfanstiel, Executive Vice President, Chief Financial Officer and Treasurer, received a cash award of $240,000 and 170,212 restricted stock units. W. Andrew Macan, Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary, received a cash award of $231,750 and 164,361 restricted stock units. The cash awards will be paid and the RSUs will vest on the earlier of June 30, 2027 or a termination of employment without cause.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
